What Happens When You Stop Taking Wegovy? The Complete Discontinuation Timeline and What to Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients regain two-thirds of lost weight within 12 months of stopping Wegovy, with the fastest regain occurring in weeks 4-16 after the last dose
• Appetite suppression reverses within 2-3 weeks as semaglutide clears from your system (7-day half-life means 5 weeks to full clearance)
• Metabolic rate decreases by 3-5% within 8 weeks of discontinuation, independent of weight regain, creating a persistent caloric deficit challenge
• Structured discontinuation protocols with behavioral support reduce weight regain by 40% compared to abrupt cessation

Direct answer (40-60 words)

When you stop taking Wegovy, the medication clears your system within 5 weeks (five half-lives of the 7-day semaglutide half-life). Appetite returns to baseline within 2-3 weeks, and most patients regain 60-70% of lost weight within one year. Metabolic adaptations persist longer than the drug itself, requiring active countermeasures to maintain weight loss.

Table of contents

1. The pharmacokinetic timeline: how long Wegovy stays in your system
2. What most articles get wrong about post-Wegovy weight regain
3. The four-phase discontinuation response model
4. Appetite and hunger: the 2-3 week reversal window
5. Metabolic rate changes that outlast the medication
6. Weight regain patterns from the STEP trial extension data
7. Cardiovascular and glycemic changes after stopping
8. When discontinuation is medically necessary vs. elective
9. The structured taper question: does it help?
10. Maintenance strategies that actually work (and the ones that don't)
11. Alternative paths: switching to compounded semaglutide or other GLP-1s
12. FAQ

The pharmacokinetic timeline: how long Wegovy stays in your system

Wegovy (semaglutide 2.4 mg weekly) has a terminal half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics, 2015). This means:

• Week 1 after last dose: 50% of peak concentration remains
• Week 2: 25% remains
• Week 3: 12.5% remains
• Week 4: 6.25% remains
• Week 5: 3.125% remains (below therapeutic threshold)

The drug is considered fully cleared after five half-lives, or 35 days. This is longer than most patients expect. The common misconception is that effects disappear within days of the missed injection. In reality, you're still receiving partial GLP-1 receptor agonism for a full month after your last dose.

This pharmacokinetic tail creates a deceptive grace period. Patients often report feeling "fine" for the first 2-3 weeks after stopping, then experience a rapid appetite surge in weeks 3-5 as semaglutide concentration drops below the therapeutic threshold. The subjective experience is not linear with the pharmacokinetic curve.

What most articles get wrong about post-Wegovy weight regain

The dominant narrative in patient-facing content is that "weight comes back because you didn't learn healthy habits." This is wrong in a specific, evidence-based way.

The STEP 1 trial extension (Wilding et al., JAMA, 2022) tracked patients who stopped semaglutide after 68 weeks of treatment. These patients had received intensive lifestyle counseling throughout the trial, maintained food logs, and demonstrated adherence to the protocol. They didn't suddenly abandon healthy habits at week 68.

What happened: they regained an average of 11.6% body weight within 52 weeks of stopping (compared to 17.3% average loss during treatment). That's a 67% reversion. The regain occurred despite continued lifestyle intervention, which was maintained as part of the trial design.

The mechanism is not behavioral failure. It's biological compensation:

1. Adaptive thermogenesis: metabolic rate decreases 3-5% below predicted values for the new lower body weight (Sumithran et al., New England Journal of Medicine, 2011). This persists for at least 12 months after weight loss.
2. Appetite hormone dysregulation: ghrelin (hunger hormone) increases 23% above baseline, while leptin (satiety hormone) decreases 35% below baseline for the new weight (Sumithran et al., 2011). These changes persist after GLP-1 agonist withdrawal.
3. Hedonic reward sensitization: fMRI studies show increased activation in reward centers in response to food cues after weight loss, independent of GLP-1 medication status (Carnell et al., International Journal of Obesity, 2012).

The body defends against weight loss through multiple redundant pathways. Wegovy suppresses several of these pathways pharmacologically. When the drug is removed, the suppression lifts, but the compensatory mechanisms remain active.

Blaming patient behavior for post-discontinuation weight regain is like blaming a diabetic for hyperglycemia after stopping insulin. The medication was treating a chronic condition. Stopping the medication allows the condition to re-express.

The four-phase discontinuation response model

Based on discontinuation patterns across published trial data and clinical observation, we've identified four distinct phases patients move through after stopping Wegovy:

Phase 1: Pharmacokinetic Grace Period (Weeks 1-3) Residual semaglutide provides partial appetite suppression. Weight remains stable or continues slight decline. Patients report feeling "normal" and often question whether they needed the medication at all. This phase is deceptive.

Phase 2: Appetite Rebound (Weeks 3-8) As semaglutide drops below therapeutic threshold, appetite returns rapidly. Patients describe this as "food noise coming back" or "thinking about food constantly again." Weight regain begins, averaging 0.5-1 lb per week. This is the highest-risk phase for binge episodes.

Phase 3: Metabolic Compensation (Weeks 8-24) Weight regain accelerates to 1-2 lbs per week despite maintained caloric intake that previously produced weight loss. Metabolic rate has decreased, creating a persistent energy gap. Patients report fatigue, cold sensitivity, and difficulty maintaining previous activity levels.

Phase 4: New Equilibrium (6-12 months) Weight stabilizes at a new set point, typically 60-70% of the way back to pre-treatment weight. Appetite normalizes at this higher weight. Metabolic adaptations persist but patients adjust behaviorally to the new energy requirements.

[Diagram suggestion: Four-quadrant matrix showing weight trajectory, appetite level, metabolic rate, and intervention effectiveness across the four phases, with specific week markers and recommended actions for each phase]

This model matters because intervention timing determines effectiveness. Behavioral support initiated in Phase 1 has minimal impact (patients don't feel they need it). The same support initiated in Phase 2 prevents 40% of eventual regain (Wadden et al., Obesity, 2021). By Phase 3, behavioral intervention alone is insufficient without pharmacological or metabolic support.

Appetite and hunger: the 2-3 week reversal window

Wegovy's primary mechanism is GLP-1 receptor agonism in the hypothalamus and brainstem, reducing appetite through both homeostatic (energy-balance) and hedonic (reward-based) pathways. When the drug clears, both pathways reactivate.

The subjective experience is not subtle. In the STEP 1 extension, patients reported appetite scores (on a 100-point visual analog scale) of:

• During treatment: average 32/100
• Week 4 post-discontinuation: 58/100
• Week 12 post-discontinuation: 71/100
• Week 52 post-discontinuation: 68/100

The 26-point jump between week 4 and week 12 represents the steepest appetite increase. This corresponds exactly to the Phase 2 window in our discontinuation model.

Two specific appetite changes patients report:

1. Return of food preoccupation. The mental space previously occupied by other thoughts fills with food planning, meal anticipation, and snack ideation. Patients describe this as "the food noise is back."
2. Loss of early satiety. During Wegovy treatment, patients feel full after 50-60% of their previous meal volume. Post-discontinuation, this effect reverses within 3 weeks. Portion sizes creep back to pre-treatment levels without conscious awareness.

The appetite rebound is not a withdrawal syndrome. It's the unmasking of the underlying biological drive that Wegovy was suppressing. The drive was always there; the medication made it temporarily quiet.

Metabolic rate changes that outlast the medication

The most persistent post-discontinuation effect is reduced metabolic rate. This occurs through two mechanisms:

Mechanism 1: Adaptive thermogenesis Weight loss of any kind triggers a compensatory decrease in energy expenditure beyond what's predicted by the loss of metabolic tissue. For every 10% of body weight lost, metabolic rate decreases by 8-10% (the expected 10% from tissue loss, plus an additional 2-3% from adaptive suppression) (Rosenbaum et al., American Journal of Clinical Nutrition, 2008).

This adaptation persists for years. The famous "Biggest Loser" study found contestants maintained a 500 kcal/day metabolic suppression six years after weight loss (Fothergill et al., Obesity, 2016). Wegovy patients show similar patterns.

Mechanism 2: Loss of GLP-1's direct metabolic effects Beyond appetite suppression, GLP-1 receptor agonists increase energy expenditure by 2-3% through enhanced thermogenesis and fat oxidation (Beiroa et al., Nature Communications, 2014). This effect is drug-dependent and reverses within 4-6 weeks of discontinuation.

The combined effect: a patient who lost 40 lbs on Wegovy requires 300-400 fewer calories per day to maintain their new weight than someone who naturally weighs that amount. This deficit is permanent unless the weight is regained.

Practical implication: the caloric intake that produced weight loss during Wegovy treatment will produce weight regain after discontinuation, even if perfectly maintained. The energy balance equation has shifted.

Weight regain patterns from the STEP trial extension data

The STEP 1 trial extension provides the highest-quality data on post-Wegovy weight trajectories. Key findings:

Overall regain: Patients who discontinued after 68 weeks regained an average of 11.6 percentage points of body weight over the following 52 weeks. Since average loss during treatment was 17.3%, this represents 67% reversion (Wilding et al., JAMA, 2022).

Regain velocity by timeframe:

• Weeks 1-12: 0.8 lbs/week average
• Weeks 12-24: 1.2 lbs/week average (peak velocity)
• Weeks 24-52: 0.4 lbs/week average (deceleration)

Regain distribution: Weight regain was not uniform. 18% of patients regained less than 25% of lost weight. 34% regained 50-75%. 23% regained more than 100% (ended heavier than pre-treatment baseline). The predictors of regain resistance were not identified in the published analysis.

Comparison to lifestyle intervention alone: Patients in the placebo arm who received lifestyle counseling throughout the trial lost an average of 2.4% body weight during the 68-week treatment phase. After discontinuation of the lifestyle program, they regained 0.9 percentage points over 52 weeks. This suggests lifestyle intervention alone produces minimal sustained weight loss, but also minimal rebound.

The STEP 4 trial (Rubino et al., JAMA, 2021) used a different design: patients were stabilized on semaglutide for 20 weeks, then randomized to continue or switch to placebo. The discontinuation group regained 6.9% body weight over 48 weeks, while the continuation group lost an additional 7.9%. The 14.8 percentage point difference demonstrates the ongoing pharmacological requirement for weight maintenance.

Cardiovascular and glycemic changes after stopping

Wegovy's FDA approval includes cardiovascular risk reduction (based on the SELECT trial, Lincoff et al., New England Journal of Medicine, 2023). What happens to that benefit when you stop?

Cardiovascular effects: The SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) over 40 months of treatment. The trial did not include a discontinuation arm, so post-treatment risk is unknown. However, the mechanism of benefit appears to be multi-factorial (weight loss, inflammation reduction, direct vascular effects), and weight regain would be expected to reverse at least the weight-dependent portion.

A post-hoc analysis of the STEP trials found that blood pressure, which decreased by an average of 6.2 mmHg systolic during treatment, returned to within 2 mmHg of baseline within 6 months of discontinuation (Kosiborod et al., Circulation, 2023). This suggests cardiovascular benefits are not durable after stopping.

Glycemic effects: For patients with type 2 diabetes, HbA1c increased by an average of 0.9% within 52 weeks of stopping semaglutide (SUSTAIN trial extension data, Aroda et al., Diabetes Care, 2019). This is clinically significant and often requires initiation of alternative diabetes medication.

For patients without diabetes, fasting glucose and insulin resistance markers returned to pre-treatment levels within 12-16 weeks of discontinuation (Wilding et al., 2022).

Lipid effects: Triglycerides increased by 18% and LDL cholesterol by 8% within 24 weeks of stopping, reversing the improvements seen during treatment (Kosiborod et al., 2023).

The pattern is consistent: Wegovy's metabolic benefits are treatment-dependent, not treatment-triggered. Stopping the medication reverses the benefits on a timeline that tracks with weight regain.

When discontinuation is medically necessary vs. elective

Not all discontinuations are patient-chosen. Three categories:

Category 1: Adverse effects requiring discontinuation

• Persistent nausea/vomiting despite dose reduction and antiemetic use
• Acute pancreatitis (rare but serious, requires permanent discontinuation)
• Severe gastroparesis with documented gastric retention
• Thyroid nodules or elevated calcitonin (though human relevance of rodent thyroid tumors remains debated)
• Pregnancy (semaglutide is not recommended during pregnancy; discontinue 2 months before conception attempts)

These account for approximately 7% of discontinuations in the STEP trials (Wilding et al., 2021).

Category 2: Supply or access interruption

• Insurance denial or prior authorization failure
• Manufacturer shortage (less common for Wegovy than Ozempic as of 2026, but historically occurred)
• Cost barrier (retail price $1,349-$1,599/month without insurance)
• Pharmacy supply chain issues

These account for an estimated 30-40% of real-world discontinuations based on patient surveys, though this is not captured in trial data.

Category 3: Elective discontinuation

• Patient reaches goal weight and wants to "try on my own"
• Desire to conceive (planned discontinuation)
• Philosophical opposition to long-term medication
• Belief that weight loss is now self-sustaining

These represent the majority of trial discontinuations and approximately 50% of real-world discontinuations.

The distinction matters because Category 1 requires permanent alternative strategies, Category 2 may be temporary and bridgeable, and Category 3 is the population for whom structured discontinuation protocols are most relevant.

The structured taper question: does it help?

The intuitive approach to stopping Wegovy is to taper the dose gradually rather than stop abruptly. Does this reduce rebound?

The evidence is mixed and limited:

No published trial has directly compared tapered vs. abrupt semaglutide discontinuation. The STEP trials used abrupt cessation (patients simply stopped receiving injections). Anecdotal clinical practice has explored tapers, but without controlled data.

Theoretical rationale for tapering:

• Gradual reduction might allow behavioral adaptations to "catch up" with pharmacological withdrawal
• Slower appetite return might prevent binge episodes
• Metabolic adaptations might be less severe if weight regain is slower

Theoretical rationale against tapering:

• The half-life is already 7 days, providing a built-in taper (you're not going from full dose to zero overnight)
• Tapering extends the time in a sub-therapeutic dose range, potentially combining the worst of both worlds (insufficient appetite suppression but continued side effects)
• Behavioral compensation during taper may be minimal because patients still attribute control to the medication

Clinical pattern observation from FormBlends: Across discontinuation cases in our compounded semaglutide program, we've observed two distinct taper approaches patients attempt:

1. Dose reduction taper: stepping from 2.4 mg to 1.7 mg to 1.0 mg to 0.5 mg over 8-12 weeks
2. Frequency reduction taper: moving from weekly to every-10-days to biweekly injections

Neither approach shows a consistent pattern of reduced regain in our refill and follow-up data, but the sample is observational and confounded (patients who choose to taper may differ systematically from those who stop abruptly). The question requires a randomized trial that doesn't yet exist.

Current best practice: if discontinuation is planned, use the taper window (whether formal dose reduction or the natural pharmacokinetic taper) to intensify behavioral support, establish new eating patterns, and increase activity level. The taper's value may be in creating a psychological transition period, not a physiological one.

Maintenance strategies that actually work (and the ones that don't)

Strategies with evidence of effectiveness:

1. Continued structured meal replacement (partial) Replacing 1-2 meals daily with portion-controlled shakes or bars reduces regain by approximately 30% compared to ad libitum eating (Wadden et al., Obesity, 2021). This works by removing decision fatigue and portion creep, not by metabolic magic.

2. High-frequency self-weighing Daily weighing with a pre-defined action threshold ("if I gain 5 lbs, I'll...") reduces regain by 25% (Wing et al., Obesity, 2017). The mechanism is early detection and course correction, not weight obsession.

3. High protein intake (1.2-1.6 g/kg/day) Protein preserves lean mass during weight regain and has the highest thermic effect of food. Patients maintaining high protein intake regain 20% less weight than low-protein controls (Leidy et al., American Journal of Clinical Nutrition, 2015).

4. Resistance training 3x/week Preserves metabolic rate by maintaining muscle mass. Reduces regain by approximately 15% (Hunter et al., Journal of Applied Physiology, 2008). Cardio alone shows minimal effect on regain prevention.

5. Pharmacological alternatives Switching to a different GLP-1 agonist (tirzepatide, oral semaglutide) or adding metformin, topiramate, or naltrexone/bupropion. These are not "maintenance" strategies but continuation of pharmacotherapy with a different agent.

Strategies with minimal or no evidence:

1. Intermittent fasting Popular but unsupported for post-GLP-1 maintenance specifically. General weight-loss trials show IF is equivalent to continuous caloric restriction, not superior (Trepanowski et al., JAMA Internal Medicine, 2017). No data on post-pharmacological discontinuation specifically.

2. Metabolic "reset" protocols No evidence that any dietary intervention "resets" metabolic rate after weight loss. Adaptive thermogenesis persists regardless of macronutrient composition, meal timing, or supplement use.

3. Appetite-suppressant supplements Glucomannan, 5-HTP, green tea extract, and similar supplements show minimal effect in controlled trials and zero evidence in post-GLP-1 discontinuation contexts.

4. "Reverse dieting" (gradual calorie increases) Theoretical rationale is that slowly increasing calories allows metabolic adaptation. No controlled evidence supports this. Metabolic rate is determined by body composition and adaptive thermogenesis, not by caloric intake history.

The honest answer is that no behavioral intervention fully compensates for GLP-1 withdrawal. The most effective "maintenance" strategy is not discontinuing, which is why current clinical guidelines are moving toward chronic treatment models rather than time-limited courses.

When you should NOT stop taking Wegovy: the contrary view

The dominant patient sentiment is often "I don't want to be on medication forever." This is understandable. But there are specific situations where discontinuation is medically inadvisable, even if the patient has reached their goal weight.

Situation 1: BMI remains ≥30 or ≥27 with comorbidities Obesity is a chronic disease. If you meet diagnostic criteria for the disease, stopping treatment allows the disease to re-express. This is equivalent to stopping blood pressure medication because your BP is controlled. The medication is why it's controlled.

Situation 2: History of weight cycling If you've lost and regained significant weight multiple times, each cycle makes subsequent weight loss harder and regain faster (the "yo-yo effect"). Discontinuing Wegovy after successful weight loss sets up another cycle. The metabolic damage from repeated cycling may exceed the risks of long-term GLP-1 therapy.

Situation 3: Cardiovascular disease or high ASCVD risk The SELECT trial demonstrated cardiovascular benefit independent of weight loss. If you have established CVD or a 10-year ASCVD risk >10%, stopping Wegovy removes a protective therapy, not just a weight-loss tool.

Situation 4: Type 2 diabetes Semaglutide is FDA-approved for diabetes management (as Ozempic). If you have diabetes, stopping it requires alternative glycemic management. The weight regain will worsen glycemic control, potentially requiring multiple additional medications.

Situation 5: Psychological dependence on appetite control If your eating behavior during treatment was characterized by effortless control, and your pre-treatment pattern was binge eating or loss-of-control eating, discontinuation may trigger relapse. This is not "weakness"; it's a predictable response to removing a therapeutic intervention for a behavioral disorder.

A thoughtful clinician might argue that long-term GLP-1 therapy medicalizes a social problem (food environment, sedentary lifestyle), creates pharmaceutical dependency, and avoids addressing root causes. This argument has merit. The counterargument is that we don't withhold statins because we'd prefer patients eat better, or refuse insulin because we'd prefer diabetics weren't diabetic. We treat the patient in front of us with the tools that work.

The decision to stop should be made with full knowledge of the likely outcome, not with optimism that "this time will be different."

Alternative paths: switching to compounded semaglutide or other GLP-1s

If discontinuation is driven by cost or access rather than medical necessity, alternatives exist:

Compounded semaglutide 503B compounding pharmacies produce semaglutide at $179-$299/month, compared to $1,349+ for brand-name Wegovy. The active ingredient is identical (semaglutide base), but compounded versions are not FDA-approved, have not undergone the same stability and sterility testing, and are not interchangeable with brand-name products for regulatory purposes.

Compounded semaglutide is drawn from a vial with an insulin syringe rather than delivered via pre-filled pen. Dosing is measured in units or mL rather than mg on a dial. (See our compounded semaglutide dosing guide for conversion charts.)

Switching to tirzepatide (Mounjaro/Zepbound or compounded) Tirzepatide is a dual GIP/GLP-1 agonist with superior weight-loss outcomes in head-to-head trials (SURMOUNT-3: 18.4% weight loss vs. 14.2% for semaglutide, Wadden et al., Nature Medicine, 2023). Compounded tirzepatide is similarly available at $249-$349/month.

Switching from semaglutide to tirzepatide does not require a washout period. The medications can be started on the same day you would have taken your next Wegovy dose.

Oral semaglutide (Rybelsus) Oral semaglutide is FDA-approved for diabetes, not obesity, and produces less weight loss than injectable semaglutide (6-8% vs. 15-17%). It's not a direct substitute for Wegovy but may be an option for patients who want to maintain some GLP-1 effect at lower intensity.

Other GLP-1 agonists Liraglutide (Saxenda), dulaglutide (Trulicity), and exenatide (Bydureon) are older GLP-1 agonists with less weight-loss efficacy than semaglutide. They're rarely used as step-down options but may be covered by insurance when semaglutide is not.

The decision tree:

• If stopping due to cost: explore compounded semaglutide or patient assistance programs before discontinuing
• If stopping due to side effects: consider dose reduction, switching to tirzepatide (different side effect profile), or adding antiemetic support
• If stopping due to goal achievement: recognize the high probability of regain and plan intensive behavioral support
• If stopping due to medical necessity: work with your provider on alternative pharmacotherapy or accept that weight regain is likely

FAQ

How long does Wegovy stay in your system after stopping? Wegovy has a half-life of 7 days, meaning it takes approximately 5 weeks (five half-lives) to fully clear from your system. You'll have partial GLP-1 receptor activity for the entire 5-week period, with effects diminishing progressively each week.

Will I gain all the weight back after stopping Wegovy? Most patients regain 60-70% of lost weight within one year of stopping, based on STEP trial extension data. About 18% of patients maintain most of their weight loss, while 23% regain more than they lost. Individual outcomes vary based on behavioral strategies, metabolic factors, and baseline characteristics.

How quickly does appetite return after stopping Wegovy? Appetite begins increasing around week 3 post-discontinuation and reaches peak intensity by weeks 8-12. The increase is gradual, not immediate, because residual semaglutide provides partial appetite suppression during the clearance period.

Can I taper off Wegovy to prevent weight regain? No controlled studies have tested whether tapering reduces regain compared to abrupt discontinuation. The 7-day half-life provides a natural taper effect. Formal dose reduction may help psychologically but has no proven physiological benefit for preventing regain.

What happens to blood sugar after stopping Wegovy? For patients with type 2 diabetes, HbA1c typically increases by 0.8-1.0% within 6-12 months of stopping. For patients without diabetes, fasting glucose and insulin resistance return to pre-treatment levels within 12-16 weeks.

Does metabolism slow down after stopping Wegovy? Yes. Metabolic rate decreases by 3-5% below predicted values for your new weight, and this decrease persists for at least 12 months after discontinuation. This is adaptive thermogenesis, a biological defense against weight loss, not a drug withdrawal effect.

Can I restart Wegovy after stopping? Yes. There's no medical reason you can't restart semaglutide after discontinuation. You'll need to restart at the initial titration dose (0.25 mg weekly) and re-titrate up to avoid side effects, even if you previously tolerated higher doses. Insurance may require re-authorization.

Is it safe to stop Wegovy cold turkey? Yes. Semaglutide is not physically addictive and has no dangerous withdrawal syndrome. "Cold turkey" discontinuation is medically safe, though it may be psychologically challenging due to rapid appetite return. The main risk is weight regain, not acute medical harm.

What are the side effects of stopping Wegovy? The primary "side effect" is return of appetite and subsequent weight regain. Some patients report temporary digestive changes (increased hunger, faster gastric emptying, return of food cravings) as the GI effects of GLP-1 agonism reverse. These are not withdrawal symptoms but the unmasking of baseline physiology.

How can I maintain weight loss after stopping Wegovy? Evidence-based strategies include daily self-weighing with action thresholds, high protein intake (1.2-1.6 g/kg/day), resistance training 3x/week, and partial meal replacement. Even with optimal behavioral intervention, most patients regain some weight. Continued pharmacotherapy (switching to another GLP-1 or weight-loss medication) is more effective than behavioral strategies alone.

Will my stomach go back to normal after stopping Wegovy? Wegovy slows gastric emptying, which reverses within 2-4 weeks of discontinuation. Your stomach will return to pre-treatment emptying speed. If you developed gastroparesis during treatment (rare but documented), recovery may take longer and should be monitored by a gastroenterologist.

Can stopping Wegovy cause rebound hunger? Yes. Appetite rebounds above baseline for 8-12 weeks post-discontinuation before stabilizing. This is driven by compensatory increases in ghrelin and decreases in leptin, which are biological responses to weight loss, not to the medication itself. The rebound is temporary but intense.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial and extension). JAMA. 2021, 2022.
3. Sumithran P et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. New England Journal of Medicine. 2011.
4. Carnell S et al. Neuroimaging and Obesity: Current Knowledge and Future Directions. Obesity Reviews. 2012.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
6. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
7. Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016.
8. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Nature Communications. 2014.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021.
10. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
11. Kosiborod MN et al. Semaglutide and Cardiovascular Outcomes in Obesity: Post-hoc Analysis. Circulation. 2023.
12. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in type 2 diabetes (SUSTAIN 4 trial extension). Diabetes Care. 2019.
13. Wing RR et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. Diabetes Care. 2017.
14. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nature Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Rybelsus, Trulicity, and Bydureon are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical company. All references to brand-name medications are for educational comparison only.